Eli Lilly and Co
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02623465
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1117
- Registration Number
- NCT02614261
- Locations
- ๐บ๐ธ
Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States
๐บ๐ธBoston Clinical Trials Inc, Boston, Massachusetts, United States
๐บ๐ธArtemis Institute for Clinical Research, San Diego, California, United States
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 986
- Registration Number
- NCT02614196
- Locations
- ๐บ๐ธ
Neurology & Neuroscience Associates, Inc., Akron, Ohio, United States
๐บ๐ธCatalina Research Institute, LLC, Montclair, California, United States
๐บ๐ธAxiom Research, Apple Valley, California, United States
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
- Conditions
- HealthyAlzheimer's DiseaseMild Cognitive Impairment
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT02614131
- Locations
- ๐บ๐ธ
Parexel Early Phase Unit at Glendale, Glendale, California, United States
๐บ๐ธCRI Lifetree, Marlton, New Jersey, United States
๐บ๐ธPRA Health Sciences, Salt Lake City, Utah, United States
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 862
- Registration Number
- NCT02614183
- Locations
- ๐บ๐ธ
Orange Grove Family Practice, Tucson, Arizona, United States
๐บ๐ธTerritory Neurology & Research Institute, Tucson, Arizona, United States
๐บ๐ธArkansas Clinical Research, Little Rock, Arkansas, United States
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 270
- Registration Number
- NCT02614287
- Locations
- ๐บ๐ธ
New England Institute for Clinical Research, Stamford, Connecticut, United States
๐บ๐ธSunrise Clinical Research, Hollywood, Florida, United States
๐บ๐ธCalifornia Medical Clinic for Headache, Santa Monica, California, United States
A Study of LY3090106 in Participants With Sjรถgren's Syndrome (SS)
- Conditions
- Sjรถgren's Syndrome
- Interventions
- Drug: LY3090106Drug: Placebo
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT02614716
- Locations
- ๐บ๐ธ
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, United States
๐บ๐ธAltoona Center for Clinical Research, Duncansville, Pennsylvania, United States
๐บ๐ธNorthEast Rheumatology, Concord, North Carolina, United States
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
- Conditions
- Migraine With or Without Aura
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3005
- Registration Number
- NCT02605174
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, Anaheim, California, United States
๐บ๐ธPharmacology Research Institute, Newport Beach, Newport Beach, California, United States
๐บ๐ธPinnacle Trials, Inc., Atlanta, Georgia, United States
A Study of LY3154207 on Sleep in Healthy Male Participants
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT02603861
- Locations
- ๐บ๐ธ
Parexel Early Phase Unit at Glendale, Glendale, California, United States
A Study of LY3113593 in Participants With Chronic Kidney Disease
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: LY3113593Drug: Placebo
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT02604160
- Locations
- ๐บ๐ธ
Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
๐บ๐ธClinical Advancement Center, PLLC, San Antonio, Texas, United States
๐บ๐ธIndiana University School of Medicine, Indianapolis, Indiana, United States